Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders

Gut

Volumn 62, Issue 1, 2013, Pages 122-130

  Metzger, Jochen ^a   Negm, Ahmed A ^b   Plentz, Ruben R ^c   Weismüller, Tobias J ^b   Wedemeyer, Jochen ^d   Karlsen, Tom H ^e   Dakna, Mohammed ^a   Mullen, William ^f   Mischak, Harald ^a,f   Manns, Michael P ^b   Lankisch, Tim O ^b  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Robert Koch Hospital Gehrden   (Germany)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD99 ANTIGEN; CD99 ANTIGEN LIKE PROTEIN 2; COLLAGEN ALPHA 1 CHAIN; COLLAGEN ALPHA 6 CHAIN; COLLAGEN TYPE I ALPHA 1; COLLAGEN TYPE I ALPHA 2; COLLAGEN TYPE II ALPHA 1; COLLAGEN TYPE III ALPHA 1; COLLAGEN TYPE XVII ALPHA 1; INTERSTITIAL COLLAGENASE; KININOGEN I; MEMBRANE ASSOCIATED PROGESTERONE RECEPTOR COMPONENT 1; OSTEOPONTIN; SODIUM POTASSIUM TRANSPORTING ADENOSINE TRIPHOSPHATE SUBUNIT GAMMA; TAMM HORSFALL GLYCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BILE DUCT CARCINOMA; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SUPPORT VECTOR MACHINE; URINALYSIS; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CLUSTER ANALYSIS; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; ELECTROPHORESIS, CAPILLARY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDE MAPPING; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

EID: 84871143909     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302047     Document Type: Article

References (32)

1. Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet 2005;366:1303-14. (Pubitemid 41416587)
2. Demols A, Marechal R, Devière J, et al. The multidisciplinary management of gastrointestinal cancer. Biliary tract cancers: from pathogenesis to endoscopic treatment. Best Pract Res Clin Gastroenterol 2007;21:1015-29. (Pubitemid 350215367)
3. Weismüller TJ, Wedemeyer J, Kubicka S, et al. The challenges in primary sclerosing cholangitis - eaetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008;48(Suppl 1):S38-57.
4. Sinakos E, Saenger AK, Keach J, et al. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clin Gastroenterol Hepatol 2011;9:434-9.
5. de Bellis M, Fogel EL, Sherman S, et al. Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc 2003;58:176-82. (Pubitemid 38220264)
6. Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011;53:1590-9.
7. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-7. (Pubitemid 34194790)
8. Weismüller TJ, Lankisch TO. Medical and endoscopic therapy of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2011;25:741-52.
9. Lankisch TO, Metzger J, Negm AA, et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011;53:875-84.
10. Schaub S, Wilkins J, Weiler T, et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int 2004;65:323-32. (Pubitemid 38037520)
11. Hortin GL, Sviridov D. Diagnostic potential for urinary proteomics. Pharmacogenomics 2007;8:237-55. (Pubitemid 46477735)
12. Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int 2010;78:1252-62.
13. Wittke S, Fliser D, Haubitz M, et al. Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A 2003;1013:173-81. (Pubitemid 37297584)
14. Neuhoff N, Kaiser T, Wittke S, et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004;18:149-56. (Pubitemid 38160349)
15. Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009;8:268-81.
16. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7:230-40. (Pubitemid 43286453)
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995;57:125-33.
18. Freund YS, Schapire RE. A decision-theoretic generalization of on-line learning and an application to boosting. J Comput Syst Sci 1997;55:119-39. (Pubitemid 127433398)
19. Zürbig P, Renfrow MB, Schiffer E, et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006;27:2111-25. (Pubitemid 43942113)
20. Brinckerhoff CE, Ruby PL, Austin SD, et al. Molecular cloning of human synovial cell collagenase and selection of a single gene from genomic DNA. J Clin Invest 1987;79:542-6. (Pubitemid 17009691)
21. Saffarian S, Collier IE, Marmer BL, et al. Interstitial collagenase is a Brownian ratchet driven by proteolysis of collagen. Science 2004;306:108-11. (Pubitemid 39451949)
22. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
23. Thongboonkerd V. Recent progress in urinary proteomics. Proteomics Clin Appl 2007;1:780-91.
24. Xue H, Lu B, Lai M. The cancer secretome: a reservoir of biomarkers. J Transl Med 2008;6:52.
25. Urtasun R, Lopategi A, George J, et al. Osteopontin, an oxidant stress-sensitive cytokine, up-regulates collagen-i via integrin alpha(V) beta(3) engagement and PI3K-pAkt- NFkappaB signaling. Hepatology 2012;55:594-608.
26. Gore-Hyer E, Shegogue D, Markiewicz M, et al. TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002;283 :F707-16. (Pubitemid 35033958)
27. Zimina EP, Fritsch A, Schermer B, et al. Extracellular phosphorylation of collagen XVII by ecto-casein kinase 2 inhibits ectodomain shedding. J Biol Chem 2007;282:22737-46. (Pubitemid 47267317)
28. Ghaffari A, Li Y, Karami A, et al. Fibroblast extracellular matrix gene expression in response to keratinocyte-releasable stratifin. J Cell Biochem 2006;98:383-93.
29. Ghahary A, Karimi-Busheri F, Marcoux Y, et al. Keratinocyte-releasable stratifin functions as a potent collagenase-stimulating factor in fibroblasts. J Invest Dermatol 2004;122:1188-97. (Pubitemid 38651094)
30. Lam E, Kilani RT, Li Y, et al. Stratifin-induced matrix metalloproteinase-1 in fibroblast is mediated by c-fos and p38 mitogen-activated protein kinase activation. J Invest Dermatol 2005;125:230-8. (Pubitemid 41648154)
31. Schilling O, Overall CM. Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat Biotechnol 2008;26:685-94. (Pubitemid 351809596)
32. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007;109:5511-19. (Pubitemid 46890577)